UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2009
VICAL INCORPORATED
(Exact name of registrant as specified in its charter)
| Delaware | 000-21088 | 93-0948554 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
10390 Pacific Center Court
San Diego, CA 92121
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code:(858) 646-1100
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into a Material Definitive Agreement. |
On May 22, 2009, Vical Incorporated entered into a securities purchase agreement with an institutional investor relating to the issuance and sale of (a) 2,000,000 shares of Vical’s common stock and (b) warrants to purchase a total of 1,000,000 shares of Vical’s common stock with an exercise price of $2.25 per share. The shares of common stock and the warrants will be sold in units consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a purchase price of $2.3125 per unit. The warrants may be exercised any time on or after the six month anniversary of the closing date of the offering and for a 90 day period thereafter. Under the terms of the transaction, Vical will sell the common stock and warrants to the institutional investor for gross proceeds of approximately $4.6 million. The closing of this offering is expected to take place on May 27, 2009, concurrent with the previously-announced offering of 6,666,667 shares of Vical’s common stock and warrants to purchase 3,333,333 shares of Vical’s common stock to two other institutional investors. This offering of securities is also taking place pursuant to the terms of a placement agency agreement between Vical and Rodman & Renshaw, LLP. Copies of the placement agency agreement and form of warrant applicable to this offering of securities are attached as Exhibits 1.1 and 4.1, respectively, to Vical’s Current Report on Form 8-K previously filed on May 22, 2009, and are incorporated herein by reference. The form of securities purchase agreement applicable to this offering of securities is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The common stock and warrants will be issued pursuant to a prospectus supplement which will be filed with the Securities and Exchange Commission, in connection with a shelf takedown from Vical’s registration statement on Form S-3 (File No. 333-159103) which became effective on May 20, 2009. A copy of the opinion of Cooley Godward Kronish LLP relating to the legality of the issuance and sale of the securities in this offering is attached as Exhibit 5.1 hereto.
The foregoing descriptions of the placement agency agreement, form of warrant and form of securities purchase agreement do not purport to be complete and are qualified in their entirety by reference to the exhibits which are incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
Exhibit No. | Description | |
| 5.1 | Opinion of Cooley Godward Kronish LLP | |
| 23.1 | Consent of Cooley Godward Kronish LLP (included in Exhibit 5.1) | |
| 99.1 | Form of Securities Purchase Agreement | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VICAL INCORPORATED | ||||||||
| Dated: May 22, 2009 | By: | /s/ Vijay B. Samant | ||||||
Vijay B. Samant President and Chief Executive Officer | ||||||||
INDEX TO EXHIBITS
Exhibit No. | Description | |
| 5.1 | Opinion of Cooley Godward Kronish LLP | |
| 23.1 | Consent of Cooley Godward Kronish LLP (included in Exhibit 5.1) | |
| 99.1 | Form of Securities Purchase Agreement | |